| Literature DB >> 22548294 |
Yin Tang1, Yang-Bing Li, Bo Wang, Ri-Yuan Lin, Mallory van Dongen, Danielle M Zurcher, Xiao-Yan Gu, Mark M Banaszak Holl, George Liu, Rong Qi.
Abstract
Although siRNA techniques have beenpan> broadly applied as a tool for genpan>e knpan>ockdownpan>, substantial challenpan>ges remainpan> inpan> achievinpan>g efficienpan>t delivery and inpan> vivo efficacy. Inpan> particular, the low efficienpan>cy of target genpan>e silenpan>cinpan>g inpan> vivo is a critical limitinpan>g step to the clinpan>ical application of siRNA therapies. Poly(amidoamine) (PAMAM) dendrimers are widely used as carriers for drug and gene delivery; however, in vivo siRNA delivery by PAMAM dendrimers remains to be carefully investigated. In this study, the effectiveness of G5 and G6 PAMAM dendrimers with 8% of their surface amines conjugated to MPEG-5000 was studied for siRNA delivery in vitro and for intramuscular in vivo delivery in mice. The results from the PEG-modified dendrimers were compared to the results from the parent dendrimers as well as Lipofectamine 2000 and INTERFERin. Both PEG-modifed dendrimers protect the siRNA from being digested by RNase and gave high transfection efficiency for FITC-labeled siRNA in the primary vascular smooth muscle cells (VSMC) and mouse peritoneal macrophages. The PEG-modified dendrimers achieved knockdown of both plasmid (293A cells) and adenovirus-mediated green fluorescence protein (GFP) expression (Cos7 cells) in vitro with efficiency similar to that shown for Lipofectamine 2000. We further demonstrated in vivo that intramuscular delivery of GFP-siRNA using PEG-modified dendrimer significantly suppressed GFP expression in both transiently adenovirus infected C57BL/6 mice and GFP transgenic mice.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22548294 PMCID: PMC3375318 DOI: 10.1021/mp3001364
Source DB: PubMed Journal: Mol Pharm ISSN: 1543-8384 Impact factor: 4.939